Mesoblast reports 84% survival in children treated with FDA-approved Ryoncil
Mesoblast (ASX:MSB) reported encouraging real-world outcomes for its FDA-approved therapy Ryoncil (remestemcel-L-rknd) in children with steroid-refractory acute graft-versus-host disease.




-8-640x360.png&w=3840&q=75)






